Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer.
Yokouchi H, Nishihara H, Harada T, Amano T, Ohkuri T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Nishimura M, Suzuki H, Dosaka-Akita H, Isobe H. Yokouchi H, et al. Among authors: ohkuri t. Oncoimmunology. 2021 Sep 18;10(1):1971430. doi: 10.1080/2162402X.2021.1971430. eCollection 2021. Oncoimmunology. 2021. PMID: 34552823 Free PMC article.
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma.
Hayashi R, Nagato T, Kumai T, Ohara K, Ohara M, Ohkuri T, Hirata-Nozaki Y, Harabuchi S, Kosaka A, Nagata M, Yajima Y, Yasuda S, Oikawa K, Kono M, Kishibe K, Takahara M, Katada A, Hayashi T, Celis E, Harabuchi Y, Kobayashi H. Hayashi R, et al. Among authors: ohkuri t. Oncoimmunology. 2020 Dec 29;10(1):1856545. doi: 10.1080/2162402X.2020.1856545. Oncoimmunology. 2020. PMID: 33457076 Free PMC article.
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma.
Kono M, Komatsuda H, Yamaki H, Kumai T, Hayashi R, Wakisaka R, Nagato T, Ohkuri T, Kosaka A, Ohara K, Kishibe K, Takahara M, Katada A, Hayashi T, Kobayashi H, Harabuchi Y. Kono M, et al. Among authors: ohkuri t. Oncoimmunology. 2022 Jan 3;11(1):2021619. doi: 10.1080/2162402X.2021.2021619. eCollection 2022. Oncoimmunology. 2022. PMID: 35003900 Free PMC article.
Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy.
Ishibashi K, Kumai T, Ohkuri T, Kosaka A, Nagato T, Hirata Y, Ohara K, Oikawa K, Aoki N, Akiyama N, Sado M, Kitada M, Harabuchi Y, Celis E, Kobayashi H. Ishibashi K, et al. Among authors: ohkuri t. Oncoimmunology. 2016 Mar 30;5(6):e1169356. doi: 10.1080/2162402X.2016.1169356. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471649 Free PMC article.
Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T, Yasukawa M, Matsuzaki J, Ohkuri T, Chamoto K, Wakita D, Azuma T, Niiya H, Miyoshi H, Kuzushima K, Oka Y, Sugiyama H, Ikeda H, Nishimura T. Tsuji T, et al. Among authors: ohkuri t. Blood. 2005 Jul 15;106(2):470-6. doi: 10.1182/blood-2004-09-3663. Epub 2005 Mar 24. Blood. 2005. PMID: 15790789 Free article.
124 results